<abstract xmlns="http://www.w3.org/1999/xhtml"><sec id="j_joepi-2018-002_s_001"><h3>Background</h3><p>Effective treatment protocols development for West syndrome (WS) is scientifically and economically significant.</p></sec><sec id="j_joepi-2018-002_s_002"><h3>Aim</h3><p>To evaluate the comparative short term efficacy and tolerability of tetracosactide at a dose of 0.03– 0.05 mg/kg and dexamethasone at a dose of 0.3–0.5 mg/kg both combined with valproate at a dose of 30–40 mg/kg/day for WS therapy. The regimen was: 1 injection daily for 10 days, following with 5 injections every other day, then 5 injections every two days, plus a valproate.</p></sec><sec id="j_joepi-2018-002_s_003"><h3>Material and Methods</h3><p>79 infants (Group 1) received tetracosactide, 18 infants (Group 2) – dexamethasone. The demographic data and the main characteristics of WS were similar in both groups.</p></sec><sec id="j_joepi-2018-002_s_004"><h3>Results</h3><p>The efficacy of tetracosactide exceeded that of dexamethasone: there were more responders to therapy in Group 1: 92.4% vs 72% (p = 0.0017). Tetracosactide produced faster results: 50.5% of patients in Group 1 experienced cessation of infantile spasms within the first 5 days of therapy versus 38.7% of patients in Group 2; infantile spasms ceased in 34% of patients in Group 1 on day 6–10, versus 22.2% of patients in Group 2. 74.6% of patients in Group 1 experienced normalization of EEG on day 10, versus 33.3% of patients in Group 2 (p = 0.04). A higher percentage of patients treated with dexamethasone exhibited multiregional activity on EEG by day 10. Tolerability was similar in both groups. All adverse effects were of mild to moderate severity</p></sec><sec id="j_joepi-2018-002_s_005"><h3>Conclusion</h3><p>Tetracosactide therapy in combination with average therapeutic doses of valproate proved to be more effective in treating WS than the combination of dexamethasone and valproate.</p></sec></abstract>

BackgroundEffective treatment protocols development for West syndrome (WS) is scientifically and economically significant.AimTo evaluate the comparative short term efficacy and tolerability of tetracosactide at a dose of 0.03– 0.05 mg/kg and dexamethasone at a dose of 0.3–0.5 mg/kg both combined with valproate at a dose of 30–40 mg/kg/day for WS therapy. The regimen was: 1 injection daily for 10 days, following with 5 injections every other day, then 5 injections every two days, plus a valproate.Material and Methods79 infants (Group 1) received tetracosactide, 18 infants (Group 2) – dexamethasone. The demographic data and the main characteristics of WS were similar in both groups.ResultsThe efficacy of tetracosactide exceeded that of dexamethasone: there were more responders to therapy in Group 1: 92.4% vs 72% (p = 0.0017). Tetracosactide produced faster results: 50.5% of patients in Group 1 experienced cessation of infantile spasms within the first 5 days of therapy versus 38.7% of patients in Group 2; infantile spasms ceased in 34% of patients in Group 1 on day 6–10, versus 22.2% of patients in Group 2. 74.6% of patients in Group 1 experienced normalization of EEG on day 10, versus 33.3% of patients in Group 2 (p = 0.04). A higher percentage of patients treated with dexamethasone exhibited multiregional activity on EEG by day 10. Tolerability was similar in both groups. All adverse effects were of mild to moderate severityConclusionTetracosactide therapy in combination with average therapeutic doses of valproate proved to be more effective in treating WS than the combination of dexamethasone and valproate.

The short-term efficacy of combined hormone therapy in West syndrome

Journal of Epileptology

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

{"article-title":"The short-term efficacy of combined hormone therapy in West syndrome"}

BackgroundEffective treatment protocols development for West syndrome (WS) is scientifically and economically significant.AimTo evaluate the comparative short...

The short-term efficacy of combined hormone therapy in West syndrome

Article Category: research-article

Pubblicato online: 15 mar 2018

Pagine: 55 - 61

Ricevuto: 25 dic 2017

Accettato: 28 feb 2018

DOI: https://doi.org/10.21307/joepi-2018-002

Parole chiave
Infantile spasms, West syndrome, hormone therapy

© 2018 Iosif V. Volkov., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

The short-term efficacy of combined hormone therapy in West syndrome

Article Category: research-article

Pubblicato online: 15 mar 2018

Pagine: 55 - 61

Ricevuto: 25 dic 2017

Accettato: 28 feb 2018

DOI: https://doi.org/10.21307/joepi-2018-002

Parole chiaveInfantile spasms, West syndrome, hormone therapy

© 2018 Iosif V. Volkov., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Parole chiave
Infantile spasms, West syndrome, hormone therapy